https://mindmedicinelaw.com/briefing/psilocybin-and-motor-function-insights-from-phase-1-study-20260807-30166The Psychedelic Journalen2026-08-08T15:08:34.292235+00:00Psilocybin and Motor Function: Insights from Phase 1 Studypsilocybin, motor function, phase 1 study, psychedelic-assisted therapy, clinical trials, dose management, adverse events, physical rehabilitation, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/long-term-safety-of-ketamine-and-esketamine-in-trd-20260807-30176The Psychedelic Journalen2026-08-08T15:07:53.291636+00:00Long-term Safety of Ketamine and Esketamine in TRDketamine, esketamine, treatment-resistant depression, long-term safety, systematic review, organ toxicity, iatrogenic addiction, clinical trials, neurocognitive effectshttps://mindmedicinelaw.com/briefing/long-term-safety-of-ketamine-and-esketamine-for-trd-20260807-30177The Psychedelic Journalen2026-08-08T15:07:42.668779+00:00Long-term Safety of Ketamine and Esketamine for TRDketamine, esketamine, treatment-resistant depression, long-term safety, clinical trials, neurocognitive effects, iatrogenic addiction, standardized protocols, systematic review, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/psilocybin-trial-for-depression-in-nhs-promising-results-20260806-30138The Psychedelic Journalen2026-08-08T15:08:23.176532+00:00Psilocybin Trial for Depression in NHS: Promising Resultspsilocybin, NHS, treatment-resistant depression, clinical trial, psychedelic therapy, mental health, public healthcare, depression treatment, psilocybin efficacy, adverse eventshttps://mindmedicinelaw.com/briefing/well-being-as-primary-endpoint-in-psychedelic-trials-20260806-30137The Psychedelic Journalen2026-08-08T15:08:10.982306+00:00Well-being as Primary Endpoint in Psychedelic Trialspsychedelic therapy, clinical trials, well-being endpoint, FDA policy, psychiatric evaluations, Delphi method, regulatory frameworks, therapeutic outcomes, symptom reduction, psychedelic researchhttps://mindmedicinelaw.com/briefing/engineered-mice-advance-psychedelic-research-in-neuroscience-20260806-30168The Psychedelic Journalen2026-08-08T15:08:03.909206+00:00Engineered Mice Advance Psychedelic Research in Neuroscienceengineered mice, psychedelic research, 5-HT2A receptor, neuropsychiatric disorders, LSD and psilocybin, molecular actions, behavioral studies, electrophysiology, drug development, ethical considerationshttps://mindmedicinelaw.com/briefing/mdma-therapy-risk-factors-in-u-s-veterans-with-ptsd-20260805-29674The Psychedelic Journalen2026-08-06T22:06:01.384533+00:00MDMA Therapy Risk Factors in U.S. Veterans with PTSDMDMA-assisted therapy, veterans, PTSD, contraindications, risk factors, clinical practice, policy implications, psychotherapy, public health, neurosciencehttps://mindmedicinelaw.com/briefing/innovative-therapies-for-treatment-resistant-depression-20260805-29696The Psychedelic Journalen2026-08-06T22:05:53.587171+00:00Innovative Therapies for Treatment-Resistant Depressiontreatment-resistant depression, ketamine, esketamine, antidepressant strategies, neurotransmission, individualized treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-als-treatment-mechanisms-and-implications-20260805-29686The Psychedelic Journalen2026-08-06T22:05:46.456776+00:00Ketamine's Role in ALS Treatment: Mechanisms and Implicationsketamine, ALS treatment, sigma-1 receptor, neuroplasticity, mitochondrial function, neurodegenerative diseases, clinical trials, FDA, therapeutic strategies, pharmacological mechanismshttps://mindmedicinelaw.com/briefing/eeg-study-links-ubes-to-brain-complexity-changes-20260804-29655The Psychedelic Journalen2026-08-07T15:06:13.883893+00:00EEG Study Links UBEs to Brain Complexity Changesunusual bodily experiences, EEG study, brain complexity, cortical hierarchy, psychedelic states, depersonalization, body-image disorders, neural dynamics, consciousness research, mental health treatmenthttps://mindmedicinelaw.com/briefing/machine-learning-and-fmri-predict-ssri-response-in-mdd-20260804-29697The Psychedelic Journalen2026-08-06T22:06:19.032641+00:00Machine Learning and fMRI Predict SSRI Response in MDDmachine learning, fMRI, SSRI, major depressive disorder, personalized treatment, neuroimaging, clinical trials, predictive modeling, mental health, pharmacotherapyhttps://mindmedicinelaw.com/briefing/exercise-modulates-depression-circuits-implications-for-therapy-20260804-29698The Psychedelic Journalen2026-08-06T22:06:10.331039+00:00Exercise Modulates Depression Circuits: Implications for Therapyexercise and depression, lateral habenula, NMHA model, non-pharmacological therapy, neuroplasticity, clinical trials in depression, mental health researchhttps://mindmedicinelaw.com/briefing/impact-of-female-sex-hormones-on-psychedelic-efficacy-20260804-29654The Psychedelic Journalen2026-08-06T22:05:36.376681+00:00Impact of Female Sex Hormones on Psychedelic Efficacypsychedelics, female sex hormones, mental health, pharmacokinetics, pharmacodynamics, clinical trials, hormonal fluctuations, 5-HT2A receptor, women's health, psychiatric disordershttps://mindmedicinelaw.com/briefing/psychedelic-enhanced-fear-extinction-rodent-study-insights-20260803-30081The Psychedelic Journalen2026-08-07T22:05:56.939067+00:00Psychedelic-Enhanced Fear Extinction: Rodent Study Insightspsychedelic research, fear extinction, rodent models, dose-effect patterns, anxiety disorders, clinical trials, psychedelic-assisted therapy, therapeutic applicationshttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-addressing-cancer-fear-new-study-insights-20260801-30070The Psychedelic Journalen2026-08-07T22:05:46.563402+00:00Psilocybin's Role in Addressing Cancer Fear: New Study Insightspsilocybin, cancer recurrence, psychedelic therapy, mental health, clinical guidelines, patient care, serotonin receptors, oncology, regulatory frameworks, psychological distresshttps://mindmedicinelaw.com/briefing/enactive-approach-to-ketamine-therapy-new-insights-20260731-29663The Psychedelic Journalen2026-08-07T15:06:25.282563+00:00Enactive Approach to Ketamine Therapy: New Insightsketamine-assisted psychotherapy, enactivism, psychedelic therapy, transformative potential, clinical research, philosophical framework, adaptive bodies, set and setting, cognitive processes, therapeutic practices